Rectal Misoprostol Versus Sublingual Misoprostol Prior to Myomectomy
NCT ID: NCT02716142
Last Updated: 2020-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
80 participants
INTERVENTIONAL
2017-03-01
2020-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sublingual Misoprostol in Decreasing Blood Loss Prior to Myomectomy
NCT02709564
Comparison Between Rectal & Sublingual Misoprostol Before Caesarian Section To Reduce Intra & Post-Operative Blood Loss
NCT02083107
Impact of Misoprostol on Blood Loss In Myomectomy Operations
NCT02061657
the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation
NCT03483142
Rectal Misoprostol and Blood Loss During Abdominal Hysterectomy
NCT02265562
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
rectal misoprostol 400 microgram
rectal misoprostol
patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
Group B
sublingual misoprostol 400 microgram
sublingual misoprostol
patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rectal misoprostol
patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
sublingual misoprostol
patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years and ≤ 50 years
* Pre-operative hemoglobin \>8 g/dl
* Ability to understand and the willingness to sign a written informed consent.
* Admissible medical/surgical history
* Five or less symptomatic uterine myomas
* All myomas are subserous or intramural.
* Uterine size less than 24 weeks pregnancy
Exclusion Criteria
* Post-menopausal women
* Patients with known bleeding/clotting disorders
* Patients with a history of gynecologic malignancy
* Hypertension.
* Cardiac and Pulmonary diseases.
* Obesity (body mass index \> 30 kg/m2).
* History of allergic reactions attributed to misoprostol
* Cases that will require intraoperative conversion of myomectomy to hysterectomy.
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Mohamed Abbas
Dr
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ahmed Abbas
Assiut, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MISOP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.